Research Analysts Issue Forecasts for PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Palvella Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($1.60) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a report on Friday, January 10th.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $12.99 on Thursday. The firm has a market cap of $17.15 million, a PE ratio of -1.07 and a beta of 0.67. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32.

Insider Buying and Selling

In related news, Director George M. Jenkins purchased 4,000 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the acquisition, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.39% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.